Teladoc Health (NYSE:TDOC) First Quarter 2025 Results

Key Financial Results

• Revenue: US$629.4m (down 2.6% from 1Q 2024).
• Net loss: US$93.0m (loss widened by 14% from 1Q 2024).
• US$0.53 loss per share (further deteriorated from US$0.49 loss in 1Q 2024).

Our free stock report includes 1 warning sign investors should be aware of before investing in Teladoc Health. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teladoc Health Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 58%.

Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.